Adaptimmune Therapeutics plc (NASDAQ:ADAP) Given Average Rating of "Moderate Buy" by Brokerages

Shares of Adaptimmune Therapeutics plc (NASDAQ:ADAP - Get Free Report) have been assigned an average rating of "Moderate Buy" from the six research firms that are presently covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12 month price target among brokers that have covered the stock in the last year is $1.83.

ADAP has been the subject of several recent research reports. Guggenheim lowered their price objective on shares of Adaptimmune Therapeutics from $3.00 to $1.75 and set a "buy" rating for the company in a research note on Wednesday, March 26th. Wells Fargo & Company dropped their price target on shares of Adaptimmune Therapeutics from $2.00 to $1.50 and set an "equal weight" rating for the company in a research note on Friday, March 21st. Jones Trading cut Adaptimmune Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Friday, April 11th. StockNews.com started coverage on Adaptimmune Therapeutics in a research note on Monday, April 14th. They set a "buy" rating for the company. Finally, HC Wainwright reduced their price target on Adaptimmune Therapeutics from $3.50 to $3.00 and set a "buy" rating on the stock in a research report on Tuesday, April 1st.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. Jane Street Group LLC boosted its holdings in Adaptimmune Therapeutics by 130.4% in the third quarter. Jane Street Group LLC now owns 174,157 shares of the biotechnology company's stock valued at $166,000 after purchasing an additional 98,581 shares in the last quarter. Virtu Financial LLC boosted its holdings in shares of Adaptimmune Therapeutics by 27.5% in the 3rd quarter. Virtu Financial LLC now owns 101,008 shares of the biotechnology company's stock valued at $96,000 after buying an additional 21,769 shares in the last quarter. FMR LLC boosted its holdings in shares of Adaptimmune Therapeutics by 3.0% in the 3rd quarter. FMR LLC now owns 1,740,900 shares of the biotechnology company's stock valued at $1,655,000 after buying an additional 50,419 shares in the last quarter. Two Sigma Advisers LP grew its position in shares of Adaptimmune Therapeutics by 492.0% in the 4th quarter. Two Sigma Advisers LP now owns 70,735 shares of the biotechnology company's stock valued at $38,000 after buying an additional 58,787 shares during the last quarter. Finally, Two Seas Capital LP acquired a new stake in Adaptimmune Therapeutics during the 4th quarter worth $7,992,000. Hedge funds and other institutional investors own 31.37% of the company's stock.

Adaptimmune Therapeutics Trading Down 0.7 %

Shares of Adaptimmune Therapeutics stock traded down $0.00 on Tuesday, reaching $0.24. The company had a trading volume of 301,922 shares, compared to its average volume of 1,771,217. The firm's 50 day moving average price is $0.39 and its two-hundred day moving average price is $0.58. The company has a debt-to-equity ratio of 0.62, a quick ratio of 3.82 and a current ratio of 3.85. Adaptimmune Therapeutics has a 52-week low of $0.20 and a 52-week high of $1.48. The firm has a market cap of $61.27 million, a PE ratio of -1.08 and a beta of 2.84.

Adaptimmune Therapeutics (NASDAQ:ADAP - Get Free Report) last posted its quarterly earnings data on Monday, March 24th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.09). The firm had revenue of $3.22 million during the quarter, compared to analysts' expectations of $16.56 million. Adaptimmune Therapeutics had a negative net margin of 25.43% and a negative return on equity of 74.15%. Sell-side analysts predict that Adaptimmune Therapeutics will post -0.14 earnings per share for the current fiscal year.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.